Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: AC2993, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 126
States / cities: Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more

Conditions: Coronary Arteriosclerosis, Myocardial Infarction
Interventions: Day Light, Room Light; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Graves' Disease
Interventions: Levothyroxine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Severe Sepsis, Septic Shock
Interventions: Not listed
Lead sponsor: Sirius Genomics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Diabetes Mellitus Type 1, Autoimmune Diabetes
Interventions: Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd); Drug · Biological
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 16 Years to 30 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions: BQ-788, BQ-123, L-Arginine, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Lactated Ringer's; Drug
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alopecia Areata
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Northridge, California • Atlanta, Georgia • Gurnee, Illinois + 7 more

Conditions: Perinatal Depression, Post Partum Depression, Depression, Postpartum, Depression
Interventions: Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 22 Years to 45 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Crohn's Disease
Interventions: Adalimumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 43
States / cities: La Jolla, California • San Francisco, California • Arvada, Colorado + 33 more

Conditions: Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate, Bicalutamide, Biospecimen Collection, Computed Tomography Angiography, Leuprolide, Prednisone, Radiation Therapy, Relugolix; Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor
Interventions: Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 6
States / cities: New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more

Conditions: Cancer-related Fatigue
Interventions: Thyrotropin releasing hormone (TRH), Placebo; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Osteoporosis, Inflammation
Interventions: Yogurt Intervention; Other
Lead sponsor: University of Massachusetts, Lowell; Other
Eligibility: 50 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lawrence, Massachusetts

Conditions: Hot Flashes
Interventions: Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 45
States / cities: Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 40 more

Conditions: Advanced Stage Parkinson's Disease
Interventions: Levodopa (Pardoprunox), Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 12 more

Conditions: Healthy
Interventions: PF-06412562 3mg BID, PF-06412562 15mg BID, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Arcadia, California • Glendale, California

Conditions: Melanoma
Interventions: Nivolumab, Ipilimumab, Cabozantinib; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey

Conditions: Wilson's Disease
Interventions: TETA 4HCl formulation, D-Penicillamine; Drug
Lead sponsor: Orphalan; Industry
Eligibility: 8 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Denver, Colorado • New Haven, Connecticut • Ann Arbor, Michigan

Conditions: Childhood Obesity
Interventions: Family Based Behavioral Treatment, Exenatide 2 mg [Bydureon], Placebo; Behavioral · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 10 Years to 12 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cystic Fibrosis
Interventions: Alpha-1 HC 100 mg, Placebo, Alpha-1 HC 200 mg; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Neurologically Impaired, Irritable Mood, Signs and Symptoms, Digestive, Sleeplessness, Chronic Pain
Interventions: Gabapentin, placebo; Drug
Lead sponsor: Gillette Children's Specialty Healthcare; Other
Eligibility: 1 Month to 16 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Retinitis Pigmentosa
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Davis, California • Los Angeles, California • San Francisco, California + 21 more

Conditions: Cyanotic Congenital Heart Disease, Anemia, Cyanosis, Congenital Heart Disease
Interventions: Epoetin Alfa and Iron, Iron; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 8 Weeks
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Impact of Daylight on Patients With Acute Myocardial Infarction

Early Levothyroxine Post Radioactive Iodine

Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue

Yogurt Supplementation to Alter Bone Biomarkers, the Gut Microbiota and Inflammation in Older Adults

Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

Brain Activation and Satiety in Children 2

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children

Oral N-acetylcysteine for Retinitis Pigmentosa

Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial